Dermatoscopic features of thin (≤2 mm Breslow thickness) vs. thick (>2 mm Breslow thickness) nodular melanoma and predictors of nodular melanoma versus nodular non-melanoma tumours: a multicentric collaborative study by the International Dermoscopy Society.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 14 04 2020
accepted: 02 07 2020
pubmed: 13 7 2020
medline: 15 5 2021
entrez: 13 7 2020
Statut: ppublish

Résumé

Thin nodular melanoma (NM) often lacks conspicuous melanoma-specific dermatoscopic criteria and escapes clinical detection until it progresses to a thicker and more advanced tumour. To investigate the dermatoscopic morphology of thin (≤2 mm Breslow thickness) vs. thick (>2 mm) NM and to identify dermatoscopic predictors of its differential diagnosis from other nodular tumours. Retrospective, morphological case-control study, conducted on behalf of the International Dermoscopy Society. Dermatoscopic images of NM and other nodular tumours from 19 skin cancer centres worldwide were collected and analysed. Overall, 254 tumours were collected (69 NM of Breslow thickness ≤2 mm, 96 NM >2 mm and 89 non-melanoma nodular lesions). Light brown coloration (50.7%) and irregular brown dots/globules (42.0%) were most frequently observed in ≤2 mm NMs. Multivariate analysis revealed that dotted vessels (3.4-fold), white shiny streaks (2.9-fold) and irregular blue structureless area (2.4-fold) were predictors for thinner NM compared to non-melanoma nodular tumours. Overall, irregular blue structureless area (3.4-fold), dotted vessels (4.6-fold) and serpentine vessels (1.9-fold) were predictors of all NM compared to non-melanoma nodular lesions. Absence of a centralized, consensus pathology review and cases selected form tertiary centres maybe not reflecting the broader community. Our study sheds light into the dermatoscopic morphology of thin NM in comparison to thicker NM and could provide useful clues for its differential diagnosis from other non-melanoma nodular tumours.

Sections du résumé

BACKGROUND BACKGROUND
Thin nodular melanoma (NM) often lacks conspicuous melanoma-specific dermatoscopic criteria and escapes clinical detection until it progresses to a thicker and more advanced tumour.
OBJECTIVE OBJECTIVE
To investigate the dermatoscopic morphology of thin (≤2 mm Breslow thickness) vs. thick (>2 mm) NM and to identify dermatoscopic predictors of its differential diagnosis from other nodular tumours.
METHODS METHODS
Retrospective, morphological case-control study, conducted on behalf of the International Dermoscopy Society. Dermatoscopic images of NM and other nodular tumours from 19 skin cancer centres worldwide were collected and analysed.
RESULTS RESULTS
Overall, 254 tumours were collected (69 NM of Breslow thickness ≤2 mm, 96 NM >2 mm and 89 non-melanoma nodular lesions). Light brown coloration (50.7%) and irregular brown dots/globules (42.0%) were most frequently observed in ≤2 mm NMs. Multivariate analysis revealed that dotted vessels (3.4-fold), white shiny streaks (2.9-fold) and irregular blue structureless area (2.4-fold) were predictors for thinner NM compared to non-melanoma nodular tumours. Overall, irregular blue structureless area (3.4-fold), dotted vessels (4.6-fold) and serpentine vessels (1.9-fold) were predictors of all NM compared to non-melanoma nodular lesions.
LIMITATIONS CONCLUSIONS
Absence of a centralized, consensus pathology review and cases selected form tertiary centres maybe not reflecting the broader community.
CONCLUSIONS CONCLUSIONS
Our study sheds light into the dermatoscopic morphology of thin NM in comparison to thicker NM and could provide useful clues for its differential diagnosis from other non-melanoma nodular tumours.

Identifiants

pubmed: 32654237
doi: 10.1111/jdv.16815
pmc: PMC8422943
mid: NIHMS1731812
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2541-2547

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2020 European Academy of Dermatology and Venereology.

Références

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1768-75
pubmed: 24588892
Australas J Dermatol. 2019 May;60(2):e119-e126
pubmed: 30450536
J Natl Cancer Inst. 2019 Dec 1;111(12):1314-1322
pubmed: 30863861
Arch Dermatol. 2008 Sep;144(9):1120-7
pubmed: 18794455
Dermatol Surg. 2014 Jun;40(6):686-90
pubmed: 24852474
Cancer. 2015 Jun 1;121(11):1827-37
pubmed: 25649671
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer. 2008 Dec 15;113(12):3341-8
pubmed: 18988292
J Dermatol. 2011 Jan;38(1):10-5
pubmed: 21175750
JAMA Dermatol. 2013 Jun;149(6):699-709
pubmed: 23553375
Expert Rev Anticancer Ther. 2018 Oct;18(10):1007-1012
pubmed: 30079779
Dermatol Pract Concept. 2014 Jan 31;4(1):59-66
pubmed: 24520516
J Am Acad Dermatol. 2018 Oct;79(4):645-651.e4
pubmed: 30241625
Br J Dermatol. 2015 Jul;173(1):106-14
pubmed: 25916655
Arch Dermatol. 2009 Apr;145(4):488-90
pubmed: 19380679
Br J Dermatol. 2011 Dec;165(6):1251-5
pubmed: 21916885
J Natl Cancer Inst. 2019 Feb 1;111(2):180-188
pubmed: 29912415
Arch Dermatol. 2005 Jun;141(6):745-50
pubmed: 15967921
Dermatol Clin. 2013 Oct;31(4):637-47, ix
pubmed: 24075551
Dermatol Clin. 2018 Oct;36(4):359-368
pubmed: 30201145
Int J Womens Dermatol. 2017 Feb 16;3(1 Suppl):S49-S51
pubmed: 28492039
Arch Dermatol. 2010 Mar;146(3):311-8
pubmed: 20231503
Prev Med Rep. 2018 Oct 06;12:203-209
pubmed: 30364862
J Am Acad Dermatol. 2010 Sep;63(3):377-86; quiz 387-8
pubmed: 20708470
Arch Dermatol. 2002 May;138(5):609-14
pubmed: 12020221
Exp Dermatol. 2018 Nov;27(11):1280-1286
pubmed: 30218634
J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1375-80
pubmed: 23176079
Br J Dermatol. 2017 Sep;177(3):645-655
pubmed: 28118479
JAMA Dermatol. 2016 May 1;152(5):546-52
pubmed: 26792406
J Am Acad Dermatol. 2016 Jun;74(6):1093-106
pubmed: 26896294
Cancer. 2002 Oct 1;95(7):1562-8
pubmed: 12237926
J Am Acad Dermatol. 2010 Sep;63(3):361-74; quiz 375-6
pubmed: 20708469
Br J Dermatol. 2017 Aug;177(2):538-540
pubmed: 27681347
Melanoma Res. 2019 Jun;29(3):221-230
pubmed: 30672881
J Eur Acad Dermatol Venereol. 2012 May;26(5):591-6
pubmed: 21585561
J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1914-1919
pubmed: 29633377
Melanoma Res. 2013 Apr;23(2):125-31
pubmed: 23358425
J Dermatol. 2017 May;44(5):507-514
pubmed: 28447355
Dermatol Pract Concept. 2014 Apr 30;4(2):69-75
pubmed: 24855580
J Am Acad Dermatol. 2019 Jan;80(1):178-188.e3
pubmed: 30165162
Arch Dermatol. 2008 Oct;144(10):1311-20
pubmed: 18936395

Auteurs

D Sgouros (D)

1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

A Lallas (A)

1st Department of Dermatology, Aristotle University, Thessaloniki, Greece.

H Kittler (H)

Department of Dermatology, Medical University of Vienna, Vienna, Austria.

A Zarras (A)

1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

A Kyrgidis (A)

Department of Clinical Pharmacology, Aristotle University, Thessaloniki, Greece.

C Papageorgiou (C)

1st Department of Dermatology, Aristotle University, Thessaloniki, Greece.

S Puig (S)

Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Universitat de Barcelona IDIBAPS, Barcelona, Spain.
CIBER de Enfermedades Raras, Instituto de Salut de Carlos III, Barcelona, Spain.

A Scope (A)

Medical Screening Institute, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

G Argenziano (G)

Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.

I Zalaudek (I)

Department of Dermatology, University of Trieste, Trieste, Italy.

M A Pizzichetta (MA)

Department of Dermatology, University of Trieste, Trieste, Italy.
Division of Medical Oncology - Preventive Oncology, National Cancer Institute, Aviano, Italy.

A Marghoob (A)

Memorial Sloan Kettering Cancer Center, Hauppauge, NY, USA.

K Liopyris (K)

1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Memorial Sloan Kettering Cancer Center, Hauppauge, NY, USA.

J Malvehy (J)

Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Universitat de Barcelona IDIBAPS, Barcelona, Spain.
CIBER de Enfermedades Raras, Instituto de Salut de Carlos III, Barcelona, Spain.

C Oikonomou (C)

1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

A Flórez (A)

Department of Dermatology, Pontevedra University Hospital, Pontevedra, Spain.

R Braun (R)

Department of Dermatology, University Hospital Zürich, Zürich, Switzerland.

H Cabo (H)

Dermatology Institute of Medical Reserch, University of Buenos Aires, Buenos Aires, Argentina.

G Nazzaro (G)

Dermatology Unit, Fondazione I.R.C.C.S. Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

S Lanssens (S)

Private practice Dermatology Maldegem, Maldegem, Belgium.

S Menzies (S)

Discipline of Dermatology, Sydney Medical School, The University of Sydney and Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

J Paoli (J)

Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Region Västra Götaland, Department of Dermatology and Venereology, Sahlgrenska University Hospital, Gothenburg, Sweden.

G Kaminska-Winciorek (G)

Department of Bone Marrow Transplantation and Onco-Hematology, Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO), Gliwice Branch, Gliwice, Poland.

C Longo (C)

Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

A Katoulis (A)

2nd Department of Dermatology-Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Z Apalla (Z)

State Clinic of Dermatology, Hospital for Skin and Venereal Diseases, Thessaloniki, Greece.

D Ioannides (D)

1st Department of Dermatology, Aristotle University, Thessaloniki, Greece.

L Thomas (L)

Department of Dermatology, Lyon University, Lyon, France.

I Tromme (I)

Department of Dermatology, King Albert II Institute, Cliniques Universitaires Saint Luc, Brussels, Belgium.

D Ogata (D)

Department of Dermatology, Saitama Medical University, Saitama, Japan.

C Desinioti (C)

1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

A Geller (A)

Department of Social and Behavioral Sciences, Harvard TH School of Public Health, Boston, MA, USA.

A Stratigos (A)

1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH